Dry Eye Disease Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

“Dry Eye Disease (DED) Market Insights, Epidemiology and Market Forecast-2028”

(Albany, US) DelveInsight launched a new report on “Dry Eye Disease (DED) Market Insights, Epidemiology and Market Forecast-2030”.

DelveInsight’s “Dry Eye Disease (DED) Market Insights, Epidemiology and Market Forecast-2028″ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of DED in EU5 (Germany, Spain, Italy, France and United Kingdom).

Some of the facts of the report

1. As per DelveInsight estimates, market size for EU5 was USD 602.62 million in 2017.

2. As per DelveInsight analysis, it is observed that, Germany had the highest prevalent population of Dry Eye Disease in EU5.

3. DelveInsight’s Analysis, it can be observed that  Dry Eye Disease cases among the age group 46–65 years are far higher in number than other age groups. It can also be observed that patients below 17 years are least prone to DED.

4. As per Delveinsight’s estimates, the total prevalent population of Dry Eye Disease in EU5 was 11,939,169 in 2017

Key benefits of the report

1. Dry Eye Disease market report covers a descriptive overview and comprehensive insight of the Dry Eye Disease epidemiology and Dry Eye Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Dry Eye Disease market report provides insights on the current and emerging therapies.
3. Dry Eye Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. Dry Eye Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Dry Eye Disease market.

Request for sample pages : https://www.delveinsight.com/sample-request/dry-eye-disease-market

 

Among the Dry Eye Disease patients, Females accounts for a higher number of Dry Eye Disease cases than Males in 7MM.”

Dry Eye Disease, also known as Dry Eye Syndrome (DES) or Keratoconjunctivitis Sicca, is a common condition when eyes do not produce enough tears or the tears evaporate too quickly, that is essential to lubricate and nourish the eye. The condition leads to eyes drying out and becoming red, swollen, and irritated. Causes for DES include decreased tear production, excessive tear evaporation, and abnormality in the production of mucus or lipids of tear layer.

The disease management basically aims to relieve the discomfort and prevent the damage to the cornea, at the front of the eye. The currently available treatment options for Dry Eye Disease depend on the severity of the condition and may include medication, surgery, and others (eyelid therapy (warm compresses and eyelid hygiene, contact lenses, and moisture chamber spectacles)).

The main symptom of dry eyes is dry and gritty feeling in the eyes. The additional symptoms include burning or itching in the eyes, foreign body sensation, excess tearing, pain and redness of the eyes, and photophobia in some cases. Sometimes, it is also associated with a stringy discharge and blurred, changing vision. Symptoms are found to worsen in dry weathers, with low humidity and higher temperatures.

According to DelveInsight’s analysis, mild cases of Dry Eye Disease are more prominent in comparison to moderate and severe cases “

The launch of the emerging therapies is expected to significantly impact Dry Eye Disease treatment scenario in the upcoming years:-
Drugs covered

  1. OC‐01/OC‐02
  2. OCU 310
  3. HMB9036
  4. Visomitin
  5. RGN‐295
  6. Travilermide ophthalmic solution
  7. KPI‐121

And many others

The key players in Dry Eye Disease market are:

  1. Oyster Point Pharma
  2. Ocugen
  3. HanAI Biopharma
  4. Mitotech Pharma
  5. ReGen Tree
  6. Mimetogen Pharmaceuticals
  7. Kala Pharmaceuticals

And many others

 

Request for sample pages : https://www.delveinsight.com/sample-request/dry-eye-disease-market

 

Table of contents

Dry Eye Disease Market Overview at a Glance

Market Share (%) Distribution of Dry Eye Disease in 2017

Market Share (%) Distribution of Dry Eye Disease in 2030

Disease Background and Overview

Introduction

Historical overview of dry eye

Classification schemes for dry eye disease

Etiology and risk factors

Causes

Signs and Symptoms

Pathology of Dry Eye Disease

Diagnosis

Epidemiology and Patient Population – EU5 Markets

Key Findings

KOL’s Views: Epidemiology

EU5 Total Prevalent Patient Population of Dry Eye Disease

Country Wise‐Epidemiology of Dry Eye Disease

The United States

EU5

Assumptions and Rationale

Germany

France

Italy

Spain

The United Kingdom

Japan

Treatment and Management of Dry Eye Disease

Unmet Needs

Marketed Drugs

IKERVIS: Santen Pharmaceutical

Product Description

Regulatory Milestones

Safety and Efficacy

Product Profile

Emerging Therapies

Visomitin: Mitotech pharma

Product Description

Other development Activities

Clinical Development

Safety and Efficacy

Advantages and Disadvantages

Product Profile

RGN‐259: ReGen Tree

Product Description

Other development Activities

Clinical Development

Safety and Efficacy

Advantages and Disadvantages

Product Profile

HBM9036: HanAll BioPharma/ Harbour BioMed

Product Description

Other development Activities

Clinical Development

Safety and Efficacy

Advantages and Disadvantages

Product Profile

NOV03: Novaliq

Product Description

Other development Activities

Clinical Development

Safety and Efficacy

Advantages and Disadvantages

Product Profile

OCU310: Ocugen

Product Description

Other development Activities

Clinical Development

Safety and Efficacy

Advantages and Disadvantages

Product Profile

KPI‐121: Kala Pharmaceuticals

Product Description

Other development Activities

Clinical Development

Safety and Efficacy

Advantages and Disadvantages

Product Profile

CyclASol: Novaliq

Product Description

Other Development Activities

Clinical Development

Safety and Efficacy

Advantages and Disadvantages

Product Profile

CEQUA: Sun Pharma

Product Description

Clinical Development

Safety and Efficacy

Advantages and Disadvantages

Product Profile

Tivanisiran: Sylentis, S.A.

Product Description

Other Development Activity

Clinical Development

Safety and Efficacy

Advantages and Disadvantages

Product Profile

Reproxalap: Aldeyra Therapeutics

Product Description

Clinical Development

Safety and Efficacy

Advantages and Disadvantages

Product Profile

Xiidra: Novartis

Product Description

Other Development Activity

Clinical Development

Safety and Efficacy

Advantages and Disadvantages

Product Profile

Dry Eye Disease: EU‐5 Market Analysis

Key Findings

KOL’s Views: Treatment & Diagnosis

Market Size of Dry Eye Disease in 7MM

Market Size of Dry Eye Disease by Therapies

Market size of Dry Eye Disease by Types

Market Outlook by Country

United States: Market Outlook

Total Market size of Dry Eye Disease

Market Size of Dry Eye Disease by Therapies

Total Market size of Dry Eye Disease by Types

EU ‐ 5 Countries: Market Outlook

Germany

Total Market size of Dry Eye Disease

Market Size of Dry Eye Disease by Therapies

Total Market size of Dry Eye Disease by Types

France

Total Market size of Dry Eye Disease

Market Size of Dry Eye Disease by Therapies

Total Market size of Dry Eye Disease by Types

Italy

Total Market size of Dry Eye Disease

Market Size of Dry Eye Disease by Therapies

Total Market size of Dry Eye Disease by Types

Spain

Total Market size of Dry Eye Disease

Market Size of Dry Eye Disease by Therapies

Total Market size of Dry Eye Disease by Types

United Kingdom

Total Market size of Dry Eye Disease

Market Size of Dry Eye Disease by Therapies

Total Market size of Dry Eye Disease by Types

Japan: Market Outlook

Total Market size of Dry Eye Disease

Market Size of Dry Eye Disease by Therapies

Total Market size of Dry Eye Disease by Types

Market Drivers

Market Barriers

Appendix

Report Methodology

DelveInsight Capabilities

Disclaimer

About DelveInsight

Related Reports:

 Dry eye disease – Pipeline Insights, 2020

The Dry eye disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Dry eye disease across the complete product development cycle, including all clinical and nonclinical stages.

Dry eye disease – Epidemiology Forecast to 2030

The Dry eye disease epidemiology covered in the report provides historical as well as forecasted Dry eye disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/